Jubilant Life Sciences, an integrated pharmaceutical industry player and the largest custom research and manufacturing services company in India, has repaid $202 million on account of outstanding Foreign Currency Convertible Bonds (FCCBs) including yield-to-maturity (YTM) of $60 million. Following the repayment, no more FCCBs are outstanding in the books.
The company has repaid all the outstanding FCCBs on time, as per schedule, in line with the terms and conditions of the FCCB instruments, showing its commitment to meet its obligation on time and demonstrating its financial strength.
Jubilant Life Sciences is an integrated pharma and life sciences company offering Life Sciences products and services to the global life sciences industry. It is the largest custom research and manufacturing services company and a leading integrated drug discovery and development solutions company out of India.
